Sylvia Hofinger, director general of the Association of the chemical industry of Austria (FCIO), the representing voice of the Austrian chemical industry, discusses the drug pricing regulations that are affecting patients´ access to innovative medicines that in turn is harming the nation´s chances of potential investments in the pharmaceutical sector, as well as the opportunities for the budding biotech industry and the future goals of the FCIO.
As the director general, could you please introduce to our international readers the Association of the chemical Industry of Austria?
"The overall economic impact of the healthcare sector is extremely important in creating a stable and predictable environment for companies to operate in that promotes innovation and flexible market access."
